ABL1 and End Stage Liver Disease: Considering that c-Abl inhibitors have been demonstrated to be effective in treating fibrotic diseases in pre-clinical trials (Beyer and Distler, 2013), we propose that simultaneous targeting of MRTF-A and c-Abl with dual inhibitors would prove promising in the intervention of end-stage liver diseases.